Pharma

Your Article Summary

See Latest Articles

New Study on Vyvanse (lisdexamfetamine dimesylate) Capsules CII Shows Administration of Vyvanse Through Two Different Routes Demonstrated a Similar Pharmacokinetic Profile
Shire, 10/27/09

Shire plc, the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention–Deficit/Hyperactivity Disorder medication, Vyvanse Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally. Specifically, the overall rate and extent of exposure to d–amphetamine, the active medication in Vyvanse, was similar in healthy adults whether they received the drug as a solution through the nose or orally as a capsule.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
Abbott, 10/21/09

Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09

Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
Lundbeck, 11/02/09

See All of Research & Development